Aurora Sterilisation today announced it has successfully raised $4,405,327 in new investment capital from investors. This significant funding round underscores the company's progress and investor confidence in its innovative approach to medical and research sterilisation technologies. The capital injection marks a key milestone for the company as it prepares for its next phase of development and market expansion.
Aurora Sterilisation is focused on advancing sterilisation practices with its Aqsaniit system. The company introduces the first non-toxic low temperature plasma sterilator designed specifically for medical and research purposes. The Aqsaniit device is capable of achieving a -6log reduction in micro-organisms within 60 minutes, operating at temperatures no higher than 40°C, and utilizes a patented sterile bag to ensure efficacy and safety.
The recently secured funds will be strategically deployed to accelerate Aurora Sterilisation's growth initiatives. Plans include enhancing research and development efforts to further advance the Aqsaniit technology, scaling operational capacity to meet anticipated demand, and expanding market reach. This investment is crucial for supporting the company's mission to provide safer and more efficient sterilisation solutions across healthcare and scientific research environments.
Looking ahead, Aurora Sterilisation aims to leverage this investment to solidify its position as a leader in low temperature sterilisation. The company anticipates that this funding will enable it to continue innovating and making its advanced sterilisation technology more broadly available to institutions worldwide, thereby contributing to improved safety and efficiency standards in critical sectors.
